alfuzosin has been researched along with Cardiovascular Diseases in 4 studies
alfuzosin: structure given in first source
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two placebo-controlled studies involving 588 patients (292 receiving SR alfuzosin 5 mg twice daily and 296 a placebo) were pooled; 51% of the patients were > or = 65 years of age and 43% had associated cardiovascular disease including hypertension and/or were receiving concomitant antihypertensive drugs." | 5.08 | Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. ( Buzelin, JM; Delauche-Cavallier, MC; Geffriaud-Ricouard, C; Roth, S; Santoni, JP, 1997) |
| "Alfuzosin (10 mg) OD is effective and well tolerated, and it has marginal effects on blood pressure, including in elderly patients and those with hypertension, ischemic heart disease or diabetes and those receiving antihypertensive agents." | 3.73 | Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, J, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hartung, R | 1 |
| Matzkin, H | 1 |
| Alcaraz, A | 1 |
| Emberton, M | 1 |
| Harving, N | 1 |
| van Moorselaar, J | 1 |
| Elhilali, M | 1 |
| Vallancien, G | 1 |
| O'Leary, MP | 1 |
| Buzelin, JM | 1 |
| Delauche-Cavallier, MC | 1 |
| Roth, S | 1 |
| Geffriaud-Ricouard, C | 1 |
| Santoni, JP | 1 |
| Souverein, PC | 1 |
| Herings, RM | 1 |
| De la Rosette, JJ | 1 |
| Man in 't Veld, AJ | 1 |
| Farmer, RD | 1 |
| Leufkens, HG | 1 |
1 review available for alfuzosin and Cardiovascular Diseases
| Article | Year |
|---|---|
Treatment and pharmacologic management of BPH in the context of common comorbidities.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Cardiovascular Diseases; Co | 2006 |
1 trial available for alfuzosin and Cardiovascular Diseases
| Article | Year |
|---|---|
Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases | 1997 |
2 other studies available for alfuzosin and Cardiovascular Diseases
| Article | Year |
|---|---|
Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Antihypertensive Agents; Cardiovascular Diseases; D | 2006 |
Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): methodological considerations.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adult; Aged; Bias; Cardiovascular Diseas | 2001 |